A Guide to PCT serms nolvadex clomid bromo Post Cycle Therapy

RagingWhoreMoan

Full Access

POST CYCLE THERAPY
When a PH/DS user consumes hormones exogenously, from outside the body, the production of natural endogenous hormones are reduced or even stopped in extreme examples. This is a result of the body self-regulating hormones. Too much testosterone and it's production is reduced, not enough and it is increase. However, when a hormone is added from outside the body in the form of a PH the body becomes overwhelmed and reduces/stops the production of testosterone. When the PH/DS user stops taking the hormonal compound at the end of a cycle there is a delay in producing natural testosterone again.

This delay between stopping PH/DS usage and restoring optimal endogenous hormonal production often lasts months without intervention. That is the LAST thing anyone would want! Without normal hormonal ranges the body can become flooded with cortisol (a stress hormone) which is highly catabolic. Furthermore without ample levels of androgen the body finds it very difficult to regulate oestrogen levels, which can result in gyno and increased fat retention. To help maintain strength and size gains endogenous hormonal equilibrium must be restored as quickly as possible.

OVER THE COUNTER POST CYCLE THERAPY
OTC PCT is more suitable for milder PH/DS' and/or shorter duration cycles. For many who find it difficult to obtain a SERM or do not want to expose themselves to the possible side effects of a SERM an OTC PCT is the obvious choice. Traditionally, OTC PCT lacked effectiveness. However recent products have addressed those short falls and now OTC PCT are a more viable option than ever. Regardless of OTC or SERM the objectives are the same - Increase testosterone and control/decrease oestrogen.




ATD (1,4,6 Androstatriene-Dione)
ATD is a suicidal A.I which means 'oestrogen rebound' is very unlikely, as such it is a preferable choice for PCT/oestrogen control. However, we do not feel it is suitable as a stand alone product. The reason for this is it's ability to increase testosterone may in actuality be limited. ATD has the potential (especially at higher dosages) to produce a steroidal metabolite known as '1,4,6 Testosterone'. Undeniably ATD is incredibly effective at controlling oestrogen both on cycle and during PCT but that covers only one aspect of a successful PCT protocol. It's ability to produce a steroidal metabolite may have a negative rather than positive effect on HPTA recovery.

ATD AS PCT
ATD: 100/100/100/75/75/50
D-AA: 3g/3g/3g/3g/3g/3g
ATD dosage is kept relatively low in an attempt to disturb HTPA recovery as little as possible whilst controlling oestrogen. D-Aspartic Acid is added to enhance testosterone recovery and make PCT more complete.

6-BROMO (6-Bromo-androstenedione)
6-Bromo is a popular OTC PCT choice. It is a competitive aromatase inhibitor meaning it competes with the androgen receptor to prevent it's aromatization to oestrogen. Unlike Suicidal A.I's the actions of 6-BROMO are reversible, thus caution should be taken to taper dosage to prevent 'oestrogen rebound'. Again consideration must be taken regarding dosage as higher dosages can be suppressive as 6-BROMO has the ability to convert to the steroidal metabolite '6-alpha-bromo-testosterone' which will have a negative effect on HPTA recovery. For this reason 6-BROMO is not recommended as a stand alone PCT, rather as part of one.

6-BROMO AS PCT
6-BROMO: 150/150/100/100/50/50
D-AA: 3g/3g/3g/3g/3g/3g
6-BROMO dosage is kept relatively low in an attempt to disturb HTPA recovery as little as possible and is gradually tapered to help reduce the possibility of oestrogen rebound when the product is ceased. D-Aspartic Acid is added to enhance testosterone recovery and make PCT more complete.

ERASE/RECOUP (Androsta-3,5-diene-7,17-dione)
Erase is another suicidal AI which means oestrogen rebound is of little concern. However Erase offers distinct advantages over ATD & 6-BROMO - it is unable to convert to a steroidal metobolite which means it will not have a negative effect on HPTA recovery, in fact the opposite it will have a positive effect. Erase also offers anti-cortisol qualities which are very welcome at any time especially PCT when cortisol levels can elevate rapidly if left unchecked. Furthermore affinity for the aromatase enzyme is actually more potent than the pharmaceutical compound 'Aromasin'. Erase is beneficial for both oestrogen control and increasing testosterone, thus it could be used stand alone although the addition of a testosterone booster is preferable.

ERASE AS PCT
Erase: 75/75/75/75/75/75
D-AA: 3g/3g/3g/3g/3g/3g
One of the most complete OTC PCT available and very cost effective especially when using 'FRL ReBoot' which contains Erase and D-AA plus cortisol and immune support offering a complete OTC PCT option. Erase and D-AA work effectively together to increase testosterone quickly as well as reduce oestrogen and cortisol levels.

Selective Estrogen Receptor Modulator's (SERM's)
Selective Estrogen Receptor Modulator's or SERM's as they are often known posses both oestrogen agonist and antagonist properties. Simplified this means SERMs act as an oestrogen in some tissues whilst blocking the actions of oestrogens in others. Agonist properties are especially beneficial in the liver as they help to regulate serum cholesterol and have a positive effect on HDL (good) cholesterol. For this reason I believe SERM's are preferable to pharmaceutical Aromatase Inhibitors (A.I's) as on cycle oestrogen control or as part of a PCT. SERM's are especially favourable during PCT as they have the ability to increase Follicle Stimulating Hormone 'FSH' and Luteinizing Hormone 'LH'. This is achieved by blocking negative feedback inhibition caused by oestrogens within the hypothalamus and piturity.
For stronger cycles we suggest the use of a SERM. I would also strongly encourage having a SERM to hand (even if you do not intend to use it), incase you should experience any oestrogenic related sides such as gyno on cycle or during PCT.

N.B Although not essential the use of an OTC PCT can offer a more complete recover when used along side a SERM PCT. For example, Shredded Labs Recoup is beneficial to stack with a SERM as it offers, cortisol control, immune support and increased libido which are all negatively effected when using a SERM solo.

Nolvadex (Tamoxifen Citrate)
The intention of this article is not to offer an extensive insight into Nolvadex. Instead I will suggest possible uses for it.

PCT: 20/20/10/10
On Cycle:10-30mg E/D
When used to mitigate oestrogenic side effects a dosage of 10-30mg is commonly administered while offending compounds are taken. It is important to note that anti-oestrogens (SERMs) may actually reduce gains on cycle, as a sufficient level of oestrogen allows compounds to exhibit most of their benefit. Therefore it is recommended that a specific need for a SERM is identified before it is administered on cycle.

Clomid (Clomiphene Citrate)
The intention of this article is not to offer an extensive insight into Clomid. Instead I will suggest possible uses for it.

PCT: 100/100/50/50
On Cycle: 50-100mg E/D (Although Nolvadex is though more appropriate for this purpose)
When used to mitigate oestrogenic side effects a dosage of 50-100mg is commonly administered while offending compounds are taken. It is important to note that anti-oestrogens (SERMs) may actually reduce gains on cycle, as a sufficient level of oestrogen allows compounds to exhibit most of their benefit. Therefore it is recommended that a specific need for a SERM is identified before it is administered on cycle.

MULTI-COMPONENT PCT
Please note that for more suppressive cycles such as stacks or bridge cycles a multi-component PCT program is recommended. Below is a suggested proven protocol:

Nolvadex: 20/20/20/20/10/10
Clomid: 100/100/100/100
hCG: 2500IU Every Other Day for The First 16 Days of PCT (Optional)
If you have access to Human Chorionic Gonadotropin 'hCG' you may also consider administering 2500IU every other day for the first 16 days.This is a proven PCT protocol and has been used in a clinical setting to successfully restore more than 100 subjects suffering from hypogonadism.

THE FINAL WORD
As aforementioned this article was never intended to be conclusive, any article which claims to be so, overlooks the rapid pace of change in the industry. However, we hope that the article offered you an insight into PH & DS and some possible applications.
 
Only thing I see wrong here, and wasnt thought to be wrong when this was written, is the HCG post cycle. The verdict is in now and the best thing you can do for yourself is to use hcg throughout a cycle, especially a heavy dosed, and long duration cycle! Your future wife will thank you when she finally wants kids, and you will to when your able to get a hard on later in life! lmao

Dont say i never did anything for you guys! lol
 
<center style="overflow-x: auto; color: rgb(51, 51, 51); font-family: Rubik, sans-serif; font-size: 16px;">
Adverse Event*Cabergoline
(n=168) 0.125 to 1 mg two times a week
Placebo
(n=20)
Number (percent)
Gastrointestinal
Nausea45 (27)4 (20)
Constipation16 (10)0
Abdominal pain9 (5)1 (5)
Dyspepsia4 (2)0
Vomiting4 (2)0
Central and Peripheral Nervous System
Headache43 (26)5 (25)
Dizziness25 (15)1 (5)
Paresthesia2 (1)0
Vertigo2 (1)0
Body As a Whole
Asthenia15 (9)2 (10)
Fatigue12 (7)0
Hot flashes2 (1)1 (5)
Psychiatric Somnolence9 (5)1 (5)
Depression5 (3)1 (5)
Nervousness4 (2)0
Autonomic Nervous System
Postural hypotension 6 (4)0
Reproductive - Female Breast pain2 (1)0
Dysmenorrhea2 (1)0
Vision
Abnormal vision2 (1)0
*Reported at ≥ 1% for cabergoline

<tbody>
</tbody>
</center>In the 8-week, double-blind period of the comparative trial with bromocriptine, DOSTINEX (at a dose of 0.5 mg twice weekly) was discontinued because of an adverse event in 4 of 221 patients (2%) while bromocriptine (at a dose of 2.5 mg two times a day) was discontinued in 14 of 231 patients (6%). The most common reasons for discontinuation from DOSTINEX were headache, nausea and vomiting (3, 2 and 2 patients respectively); the most common reasons for discontinuation from bromocriptine were nausea, vomiting, headache, and dizziness or vertigo (10, 3, 3, and 3 patients respectively). The incidence of the most common adverse events during the double-blind portion of the comparative trial with bromocriptine is presented in the following table.
Incidence of Reported Adverse Events During the 8-Week, Double-Blind Period of the Comparative Trial With Bromocriptine
<center style="overflow-x: auto; color: rgb(51, 51, 51); font-family: Rubik, sans-serif; font-size: 16px;">
Adverse Event*Cabergoline
(n=221)
Bromocriptine
(n=231)
Number (percent)
Gastrointestinal
Nausea63 (29)100 (43)
Constipation15 (7)21 (9)
Abdominal pain12 (5)19 (8)
Dyspepsia11 (5)16 (7)
Vomiting9 (4)16 (7)
Dry mouth5 (2)2 (1)
Diarrhea4 (2)7 (3)
Flatulence4 (2)3 (1)
Throat irritation2 (1)0
*Toothache2 (1)0
Central and Peripheral Nervous System
Headache58(26)62(27)
Dizziness38(17)42(18)
Vertigo9 (4)10 (4)
Paresthesia5 (2)6 (3)
Body As a Whole
Asthenia13 (6)15 (6)
Fatigue10 (5)18 (8)
Syncope3 (1)3 (1)
Influenza-like symptoms2 (1)0
Malaise2 (1)0
Periorbital edema2 (1)2 (1)
Peripheral edema2 (1)1
Psychiatric
Depression7 (3)5 (2)
Somnolence5 (2)5 (2)
Anorexia3 (1)3 (1)
Anxiety3 (1)3 (1)
Insomnia3 (1)2 (1)
Impaired concentration2 (1)1
Nervousness2 (1)5 (2)
Cardiovascular
Hot flashes6 (3)3 (1)
Hypotension3 (1)4 (2)
Dependent edema2 (1)1
Palpitation2 (1)5 (2)
Reproductive - Female
Breast pain5 (2)8 (3)
Dysmenorrhea2 (1)1
Skin and Appendages
Acne3 (1)0
Pruritus2 (1)1
Musculoskeletal
Pain4 (2)6 (3)
Arthralgia2 (1)0
Respiratory
Rhinitis2 (1)9 (4)
Vision
Abnormal vision2 (1)2 (1)
*Reported at ≥ 1% for cabergoline

<tbody>
</tbody>
</center>
 
Back
Top